Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRbeta and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is currently in Phase III clinical trial in advanced hepatocellular carcinoma.
CAS Number:
[319460-85-0]
Application Notes:
AXB
* VAT and and shipping costs not included. Errors and price changes excepted